Literature DB >> 18646007

Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures.

Eiji Miyoshi1, Miyako Nakano.   

Abstract

Changes in oligosaccharide structures have been reported in certain types of malignant transformation and thus can be used as tumor markers in certain types of cancer. In the case of pancreatic cancer (PC) cell lines, a variety of fucosylated proteins are secreted into the conditioned media. To identify fucosylated proteins in the sera of patients with PC, we performed Western blot analysis using Aleuria Aurantia Lectin (AAL), which is specific for fucosylated structures. An approximately 40 kD protein was found to be highly fucosylated in PC and N-terminal analysis revealed that it was the beta chain of haptoglobin. While the appearance of fucosylated haptoglobin has been reported in other diseases such as hepatocellular carcinoma, liver cirrhosis, gastric cancer, and colorectal cancer, the incidence was significantly higher in the case of PC. Fucosylated haptoglobin was observed more frequently at the advanced stage of PC and disappeared after operation. Haptoglobin has four sites of N-glycans and site-directed oligosaccharide analysis involving MS was performed. Site-specific increases in fucosylation of bi-antennary glycans of sites 2 and 4, and of tri-antennary glycans of all sites were observed in PC, compared to in normal volunteers and chronic pancreatitis. Therefore, increases in fucosylation seem to be not due to inflammation, but cancer itself. Coculturing of a human hepatoma cell line, Hep3B, with PC cells-induced production of fucosylated haptoglobin, suggesting that PC produces a factor that induces the production of fucosylated haptoglobin. On clinical investigation of 100 cases of colorectal cancer, cases in which it was located near the liver showed a higher positive rate of fucosylated haptoglobin, suggesting that the location of the cancer might also be an important factor for fucosylated haptoglobin if cancer tissues produce such inducible factors. Thus, fucosylated haptoglobin could become a novel tumor marker for PC and complicated mechanisms would be involved in its production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646007     DOI: 10.1002/pmic.200800046

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  38 in total

1.  Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.

Authors:  Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

2.  A strategy for precise and large scale identification of core fucosylated glycoproteins.

Authors:  Wei Jia; Zhuang Lu; Yan Fu; Hai-Peng Wang; Le-Heng Wang; Hao Chi; Zuo-Fei Yuan; Zhao-Bin Zheng; Li-Na Song; Huan-Huan Han; Yi-Min Liang; Jing-Lan Wang; Yun Cai; Yu-Kui Zhang; Yu-Lin Deng; Wan-Tao Ying; Si-Min He; Xiao-Hong Qian
Journal:  Mol Cell Proteomics       Date:  2009-01-12       Impact factor: 5.911

3.  Core-6 fucose and the oligomerization of the 1918 pandemic influenza viral neuraminidase.

Authors:  Zhengliang L Wu; Hui Zhou; Cheryl M Ethen; Vernon N Reinhold
Journal:  Biochem Biophys Res Commun       Date:  2016-03-21       Impact factor: 3.575

Review 4.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

5.  Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.

Authors:  Petr Pompach; Zuzana Brnakova; Miloslav Sanda; Jing Wu; Nathan Edwards; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-06       Impact factor: 5.911

6.  Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease.

Authors:  Miloslav Sanda; Petr Pompach; Zuzana Brnakova; Jing Wu; Kepher Makambi; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-06       Impact factor: 5.911

Review 7.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 8.  Glycomics and disease markers.

Authors:  Hyun Joo An; Scott R Kronewitter; Maria Lorna A de Leoz; Carlito B Lebrilla
Journal:  Curr Opin Chem Biol       Date:  2009-09-21       Impact factor: 8.822

Review 9.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

10.  Towards an integrated proteomic and glycomic approach to finding cancer biomarkers.

Authors:  Allen D Taylor; William S Hancock; Marina Hincapie; Naoyuki Taniguchi; Samir M Hanash
Journal:  Genome Med       Date:  2009-06-04       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.